FDA Opens Door to Single Phase 3 Trial for Acurx's CDI Drug, Potentially Accelerating Approval
ACXP is trading near its 52-week low of $1.326 (9.4% above the low) on light trading volume (0.3× avg).
Summary
Acurx received FDA meeting minutes outlining a potential streamlined path to approval for ibezapolstat in C. difficile infection. The agency indicated that a single successful Phase 3 trial (IBZ-ASPIRE), combined with supportive data from the planned IBZ-PATHFINDER trial in recurrent CDI, could suffice for an NDA covering both acute treatment and reduction of recurrence. This is a significant regulatory de-risking event for a micro-cap company with a going concern warning. Trial start-up activities for IBZ-PATHFINDER have begun, with enrollment expected in the next few months, though the pivotal IBZ-ASPIRE trial remains subject to funding. The news follows a May 2026 highlight of general FDA guidance for CDI drugs, but today's update provides concrete, company-specific feedback that materially improves the drug's probability of success and potential timeline. The FDA has provided further regulatory guidance to Acurx for the ibezapolstat clinical development program.
At the time of this announcement, ACXP was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2M. The 52-week trading range was $1.33 to $8.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.